Serum proteins may facilitate the identification of Kawasaki disease and promote in vitro neutrophil infiltration

• Published in: Scientific reports 2020-09, Vol.10 (1), p.15645-15645, Article 15645
• Main Authors: Li, Sung-Chou, Tsai, Kuo-Wang, Huang, Lien-Hung, Weng, Ken-Pen, Chien, Kuang-Jen, Lin, Yuyu, Tu, Chi-Ying, Lin, Pei-Hsien
• Format: Article
• Language: English
• Subjects: 631/250; 692/308; 692/4017; 692/4023; 692/420; 692/53; 692/699; Biomarkers - blood; Blood Proteins - metabolism; DNA Methylation; Female; Humanities and Social Sciences; Humans; Infant; Male; Mucocutaneous Lymph Node Syndrome - blood; Mucocutaneous Lymph Node Syndrome - genetics; Mucocutaneous Lymph Node Syndrome - immunology; Mucocutaneous Lymph Node Syndrome - therapy; multidisciplinary; Neutrophil Infiltration; S100A12 Protein - blood; S100A12 Protein - immunology; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-72695-z

Kawasaki disease (KD) usually affects the children younger than 5 years of age and subsequently causes coronary artery lesions (CALs) without timely identification and treatment. Developing a robust and fast prediction method may facilitate the timely diagnosis of KD, significantly reducing the risk of CALs in KD patients. The levels of inflammatory serum proteins dramatically vary during the onsets of many immune diseases, including in KD. However, our understanding of their pathogenic roles in KD is behind satisfaction. The purpose of this study was to evaluate candidate diagnostic serum proteins and the potential mechanism in KD using iTRAQ gel-free proteomics. We enrolled subjects and conducted iTRAQ gel-free proteomics to globally screen serum proteins followed by specific validation with ELISA. Further in vitro leukocyte trans-endothelial model was also applied to investigate the pathogenesis roles of inflammatory serum proteins. We identified six KD protein biomarkers, including Protein S100-A8 (S100A8), Protein S100-A9 (S100A9), Protein S100-A12 (S100A12), Peroxiredoxin-2 (PRDX2), Neutrophil defensin 1 (DEFA1) and Alpha-1-acid glycoprotein 1 (ORM1). They enabled us to develop a high-performance KD prediction model with an auROC value of 0.94, facilitating the timely identification of KD. Further assays concluded that recombinant S100A12 protein treatment activated neutrophil surface adhesion molecules responsible for adhesion to endothelial cells. Therefore, S100A12 promoted both freshly clinically isolated neutrophils and neutrophil-like cells to infiltrate through the endothelial layer in vitro. Finally, the antibody against S100A12 may attenuate the infiltration promoted by S100A12. Our result demonstrated that evaluating S100A8, S100A9, S100A12, PRDX2, DEFA1 and ORM1 levels may be a good diagnostic tool of KD. Further in vitro study implied that S100A12 could be a potential therapeutic target for KD.